GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » EPS (Diluted)

Ablynx NV (XBRU:ABLXS) EPS (Diluted) : €0.00 (TTM As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV EPS (Diluted)?

Ablynx NV's Earnings per Share (Diluted) for the six months ended in Dec. 2017 was €0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was €0.00.

Ablynx NV's EPS (Basic) for the six months ended in Dec. 2017 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2017 was €0.00.

Ablynx NV's EPS without NRI for the six months ended in Dec. 2017 was €0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2017 was €0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was -90.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -20.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Ablynx NV's highest 3-Year average EPS without NRI Growth Rate was 37.20% per year. The lowest was -90.90% per year. And the median was -5.80% per year.


Ablynx NV EPS (Diluted) Historical Data

The historical data trend for Ablynx NV's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV EPS (Diluted) Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ablynx NV's EPS (Diluted)

For the Biotechnology subindustry, Ablynx NV's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ablynx NV's PE Ratio falls into.



Ablynx NV EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Ablynx NV's Diluted EPS for the fiscal year that ended in Dec. 2017 is calculated as

Diluted EPS (A: Dec. 2017 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-108.532-0)/43.708
=-2.48

Ablynx NV's Diluted EPS for the quarter that ended in Dec. 2017 is calculated as

Diluted EPS (Q: Dec. 2017 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-83.208-0)/43.120
=-1.93

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV  (XBRU:ABLXS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ablynx NV EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Ablynx NV's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV (XBRU:ABLXS) Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines